Abstract:Objective: To explore the application value of artificial liver support system in the clinical treatment of coronavirus disease 2019 (COVID-19) patients with cytokine storm. Methods: Six cases of severe or critically severe COVID-19 patients treated in The First Affiliated Hospital, College of Medicine, Zhejiang University from January 22 to February 4, 2020 were recruited, and all of them received artificial liver support treatment. Statistical analysis was carried out on the change of cytokines (TNF-alpha, IL-10, IL 6, IFN-gamma, IL-2, IL-4), inflammation-related indicators (white blood cell, neutrophil, lymphocyte, C-reactive protein and procalcitonin), immune-related indicators (B lymphocyte percentage, natural killer cell percentage, CD3+CD4+CD8 T cell percentage), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the 6 patients before and after treatment, and the proportions of patients with abnormal indicators were analyzed as well. In addition, computed tomography (CT) was used to observe the absorption of pulmonary lesions before and after the artificial liver support treatment. Results: The levels of cytokines (IL-6 and IL-10) were effectively reduced in the 6 patients after treatment with the artificial liver support system. Meanwhile, the proportions of patients with abnormal TNF-alpha, IL-10, IL-6 and IFN-gamma were all decreased (p < 0.05). The levels of inflammation-related indicators including white blood cell, C reactive protein and procalcitonin, and the proportions of patients with these abnormal indicators were both significantly reduced (p < 0.05). The level of neutrophil was not effectively reduced before and after the treatment, but the proportion was significantly reduced (p < 0.05). However, the abnormality of lymphocyte in the patients was not improved. There was no significant difference in immune-related indicators, AST and ALT before and after the treatment (p < 0.05). CT imaging showed that the artificial liver support treatment contributed to absorption of pulmonary lesions. Conclusions: The artificial liver support system had a great clinical effect in the treatment of cytokine storm and inflammation in COVID-19 patients, and it could promote the absorption of infected lesions.

Inflammatory cytokines depletion for severe COVID-19 infectious pneumonia: a case report

Critically Ill Patients with COVID-19 with ECMO and Artificial Liver Plasma Exchange

Integrated therapeutic plasma exchange and traditional Chinese medicine treatment in a patient with severe COVID-19: A case report

Application Value of Artificial Liver Support System in the Treatment of Cytokine Storm in Patients with COVID-19

Efficacy of therapeutic plasma exchange in severe COVID‐19 patients

Clinical and Pathological Investigation of Patients with Severe COVID-19

Convalescent plasma therapy for patients with severe COVID-19: A case series study

Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report

Blood Purification in Severe and Critical COVID-19 Patients: A Case Series of 5 Patients

Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study

Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction

What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Advances in the treatment of cytokine inhibitors in COVID-19

Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

Effectiveness Of Convalescent Plasma Therapy For Covid-19 Patients In Hunan, China

Inflammation Characteristics And Anti-Inflammation Treatment With Tocilizumab Of Severe/Critical Covid-19 Patients: A Retrospective Cohort Study

Why Tocilizumab Could Be an Effective Treatment for Severe COVID-19?